CLINICAL MANUFACTURE AND SUPPLY AGREEMENTClinical Manufacture and Supply Agreement • September 27th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 27th, 2013 Company Industry JurisdictionTHIS CLINICAL MANUFACTURE AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of December 22, 2005 (the “CSA Effective Date”), by and between OCERA THERAPEUTICS, INC. (“Ocera”), a Delaware corporation, having an address of 11622 El Camino Real, Suite 100, San Diego, CA 92130, United States of America, and KUREHA CORPORATION, a Japanese corporation (“Kureha”), having an address of 3-3-2, Nihonbashi Hama-cho, Chuo-ku, Tokyo 103-8552, Japan.
RESTATED LICENSE AGREEMENTLicense Agreement • September 27th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 27th, 2013 Company Industry JurisdictionTHIS RESTATED LICENSE AGREEMENT (the “Agreement”) is entered into as of March 6th, 2008 (the “Effective Date”) by and between KUREHA CORPORATION, a Japanese corporation (“Kureha”), having an address of 3-3-2, Nihonbashi-Hamacho, Chuo-ku, Tokyo 103-8552, Japan, and OCERA THERAPEUTICS, INC., a Delaware corporation (“Ocera”), having an address of 12651 High Bluff Drive, Suite 230, San Diego, CA 92130, United States of America.
AGREEMENTConfidentiality Agreement • September 27th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 27th, 2013 Company IndustryThis Agreement (hereinafter called “Agreement”) is made this April 5th, 2012 by and between Kureha Corporation, a Japanese corporation (hereinafter called “Kureha”), with its principal offices at 3-3-2, Nihonbashi-Hamacho, Chuo-ku, Tokyo 103-8552, Japan and Ocera Therapeutics, Inc., a Delaware corporation (hereinafter called “Ocera”), with its principal offices at 12651 High Bluff Drive, Suite 230, San Diego, CA 92130, the United States of America.
WHEREASLicense Agreement • September 27th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
Contract Type FiledSeptember 27th, 2013 Company Industry Jurisdictioncertain milestone events, milestone payments and Ocera’s development and commercialization obligations, as set out in the amendments to the Amended and Restated Agreement attached as a Schedule to this Deed with effect from the date of
COMMERCIAL MANUFACTURE AND SUPPLY AGREEMENTCommercial Manufacture and Supply Agreement • September 27th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 27th, 2013 Company Industry JurisdictionTHIS COMMERCIAL MANUFACTURE AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of November 1st, 2007 (the “Effective Date”), by and between OCERA THERAPEUTICS, INC. (“Ocera”), a Delaware corporation, having an address of 12651 High Bluff Drive, Suite 230, San Diego, CA 92130, United States of America, and KUREHA CORPORATION, a Japanese corporation (“Kureha”), having an address of 3-3-2, Nihonbashi Hama-cho, Chuo-ku, Tokyo 103-8552, Japan.